515 related articles for article (PubMed ID: 19939209)
1. Annual disease burden due to human papillomavirus 16 and 18 infections in Finland.
Syrjänen KJ
Scand J Infect Dis Suppl; 2009; 108():2-32. PubMed ID: 19939209
[TBL] [Abstract][Full Text] [Related]
2. Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland.
Syrjänen KJ
Scand J Infect Dis Suppl; 2009; 107():3-32. PubMed ID: 19408160
[TBL] [Abstract][Full Text] [Related]
3. Global burden of human papillomavirus and related diseases.
Forman D; de Martel C; Lacey CJ; Soerjomataram I; Lortet-Tieulent J; Bruni L; Vignat J; Ferlay J; Bray F; Plummer M; Franceschi S
Vaccine; 2012 Nov; 30 Suppl 5():F12-23. PubMed ID: 23199955
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...
Prescrire Int; 2007 Jun; 16(89):91-4. PubMed ID: 17582921
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of high-risk human papillomavirus type 16/18 infection among women with normal cytology: risk factor analysis and implications for screening and prophylaxis.
Gupta S; Sodhani P; Sharma A; Sharma JK; Halder K; Charchra KL; Sardana S; Singh V; Sehgal A; Das BC
Cytopathology; 2009 Aug; 20(4):249-55. PubMed ID: 19018810
[TBL] [Abstract][Full Text] [Related]
6. How much cervical cancer in Australia is vaccine preventable? A meta-analysis.
Brotherton JM
Vaccine; 2008 Jan; 26(2):250-6. PubMed ID: 18068276
[TBL] [Abstract][Full Text] [Related]
7. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions.
Vinokurova S; Wentzensen N; Kraus I; Klaes R; Driesch C; Melsheimer P; Kisseljov F; Dürst M; Schneider A; von Knebel Doeberitz M
Cancer Res; 2008 Jan; 68(1):307-13. PubMed ID: 18172324
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
Barnabas RV; Laukkanen P; Koskela P; Kontula O; Lehtinen M; Garnett GP
PLoS Med; 2006 May; 3(5):e138. PubMed ID: 16573364
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of human papillomaviruses (HPV) in benign and malignant tumors of the upper respiratory tract.
Shen J; Tate JE; Crum CP; Goodman ML
Mod Pathol; 1996 Jan; 9(1):15-20. PubMed ID: 8821950
[TBL] [Abstract][Full Text] [Related]
10. HPV type 18 is more oncopotent than HPV16 in uterine cervical carcinogenesis although HPV16 is the prevalent type in Chennai, India.
Berlin Grace VM
Indian J Cancer; 2009; 46(3):203-7. PubMed ID: 19574671
[TBL] [Abstract][Full Text] [Related]
11. Behavioral and sociodemographic risk factors for serological and DNA evidence of HPV6, 11, 16, 18 infections.
Wiley DJ; Masongsong EV; Lu S; Heather L S; Salem B; Giuliano AR; Ault KA; Haupt RM; Brown DR
Cancer Epidemiol; 2012 Jun; 36(3):e183-9. PubMed ID: 22277329
[TBL] [Abstract][Full Text] [Related]
12. [Human papillomavirus and carcinoma of the cervix vaccines against the human papillomavirus-promise of an efficacious prevention].
Kohl I
Klin Mikrobiol Infekc Lek; 2006 Jun; 12(3):91-7. PubMed ID: 17051469
[TBL] [Abstract][Full Text] [Related]
13. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
14. Women with HIV are more commonly infected with non-16 and -18 high-risk HPV types.
McKenzie ND; Kobetz EN; Hnatyszyn J; Twiggs LB; Lucci JA
Gynecol Oncol; 2010 Mar; 116(3):572-7. PubMed ID: 19906410
[TBL] [Abstract][Full Text] [Related]
15. Distribution of human papillomavirus types in anogenital warts of men.
Chan PK; Luk AC; Luk TN; Lee KF; Cheung JL; Ho KM; Lo KK
J Clin Virol; 2009 Feb; 44(2):111-4. PubMed ID: 19097933
[TBL] [Abstract][Full Text] [Related]
16. Clonal history of papillomavirus-induced dysplasia in the female lower genital tract.
Vinokurova S; Wentzensen N; Einenkel J; Klaes R; Ziegert C; Melsheimer P; Sartor H; Horn LC; Höckel M; von Knebel Doeberitz M
J Natl Cancer Inst; 2005 Dec; 97(24):1816-21. PubMed ID: 16368943
[TBL] [Abstract][Full Text] [Related]
17. On the etiology of anal squamous carcinoma.
Frisch M
Dan Med Bull; 2002 Aug; 49(3):194-209. PubMed ID: 12238281
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology of mucosal human papillomavirus infection and associated diseases.
Trottier H; Burchell AN
Public Health Genomics; 2009; 12(5-6):291-307. PubMed ID: 19684442
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
20. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
Goldie SJ; O'Shea M; Diaz M; Kim SY
Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
